Today ithere are 800 stores across Canada and if they go to 3,000 stores we think for Aphria that's another $200 million, $300 million for sales. We anticipate margins staying in that 50% to 54% range going forward. You will see are margins continuously improve through our CC Pharma distribution company as well, which will sell more and more cannabis that are higher-margin products. There's a big, big opportunity in Germany and that's why we acquired CC Pharma for that distribution to be able to sell medical cannabis into the drug stores with high margin products. As you heard us say, our first shipment went a couple of weeks ago, and hopefully that continues more and more. I think Germany will be the first country in the EU that will legalize recreational cannabis, and there's been plenty of discussions there. And if and when that happens we will be there ready with our facilities, having won the tenders and its a big, big opportunity.
Aphria currently maintains operations in Germany, Italy, Malta, Colombia, and Argentina. As well as strategic relationships in Israel, Denmark, and Poland. Every day we get calls from MSOs and we get calls from cannabis companies looking to do something with Aphria in the U.S. I think on legalization that there'll be plenty of opportunities for us to go into different states to acquire strategically. Align with different companies, and with our balance sheet do it if there are changes that will allow Aphria to enter the US. I'm not going to focus on the US not knowing what's going to happen there as those cannabis companies that bought percentages of MSOs and held them haven't been able to effectively do anything with them and getting earnings from them has not been the right thing for shareholders. But once we know what the state of the landscape looks like from legalization, there's so much that we'll bring to the U.S., I think we'll have our opportunities to be able to decide which is the best one for us.